A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer

NCT07263386 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

460

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma

Interventions

DRUG: Sintilimab
DRUG: SOX Chemotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University